Improvement in pregnancy outcomes in couples with immunologically male infertility undergoing prednisolone treatment and conventional in vitro fertilization preceded by sperm penetration assay: a randomized controlled trial

Purpose Anti-sperm antibodies (ASA) in men impair not only sperm motility but also fertilization and conception. However, utilization of corticosteroids to suppress ASA has shown variable pregnancy outcomes. This controversy is also extended to include the usefulness of conventional in vitro fertili...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Endocrine 2017-12, Vol.58 (3), p.448-457
Hauptverfasser: Taiyeb, Ahmed M., Ridha-Albarzanchi, Mundhir T., Taiyeb, Shereen M., Kanan, Zuhair A., Alatrakchi, Shahla K., Kjelland, Michael E., Muhsen-Alanssari, Saeeda A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose Anti-sperm antibodies (ASA) in men impair not only sperm motility but also fertilization and conception. However, utilization of corticosteroids to suppress ASA has shown variable pregnancy outcomes. This controversy is also extended to include the usefulness of conventional in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) in treatments of men with ASA. This study was therefore designed to define factors contributing to these inconsistent results. Methods Infertile men having ASA ( n  = 241) were randomly assigned for treatment with or without prednisolone for three cycles each of 21 days of their partner’s menstrual cycles. Control and treated men underwent then human sperm penetration assay (SPA), of hamster oocytes, to diagnose men with impaired sperm fusogenic capacity. Men with positive or negative SPA results were admitted to conventional IVF or ICSI programs, respectively. Results Treated patients had improved sperm motility and progressive motility when compared to control patients ( P  
ISSN:1355-008X
1559-0100
DOI:10.1007/s12020-017-1446-7